INMAZEB- atoltivimab, maftivimab and odesivimab injection, solution
Regeneron Pharmaceuticals, Inc.
INMAZEB is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection [see Dosage and Administration (2.2), and Clinical Studies (14)].
Limitations of Use
The efficacy of INMAZEB has not been established for other species of the Ebolavirus and Marburgvirus genera.
Zaire ebolavirus can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Zaire ebolavirus strains when deciding whether to use INMAZEB.
INMAZEB is a combination of three human monoclonal antibodies co-formulated in a 1:1:1 ratio of atoltivimab, maftivimab, and odesivimab. INMAZEB is available as two different strength presentations, containing either 16.67 mg of each antibody per mL or 33.33 mg of each antibody per mL [see Dosage Forms and Strengths (3)].
The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion as shown in Table 1 [see Dosage and Administration (2.2)].
INMAZEB must be prepared and administered under the supervision of a healthcare provider. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. INMAZEB should be clear to slightly opalescent, colorless to pale yellow solution that is free from visible particulates. Discard the vial if the solution is cloudy, discolored or contains particulate matter.
Preparation for Intravenous Infusion
- The recommended dosage is based on 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg. For example, a patient weighing 50 kg the recommended dosage is 2,500 mg of atoltivimab, 2,500 mg of maftivimab, and 2,500 mg of odesivimab.
- Determine the number of vials needed based on the calculated dose in volume (mL).
- The number of vials needed depends on the INMAZEB strength used. Refer to Table 1 for the corresponding volume per kg needed to withdraw from each available strength presentation to prepare dose.
- Multiple INMAZEB vials may be needed. Each vial contains 14.5 mL of INMAZEB solution, regardless of the strength presentation. For example, for a 50 kg patient, the volume of INMAZEB needed is 150 mL (11 vials) if using the 16.67 mg/16.67 mg/16.67 mg per mL solution or 75 mL (6 vials) if using the 33.33 mg/33.33 mg/33.33 mg per mL solution.
|When Using the||When Using the|
|241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL||483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL|
|(16.67 mg /16.67 mg /16.67 mg per mL) Solution||(33.33 mg/33.33 mg /33.33 mg per mL) Solution|
|Withdraw 3 mL of solution per kg to prepare the dose||Withdraw 1.5 mL of solution per kg to prepare the dose|
- Do not shake the vial.
- Prior to intravenous infusion, INMAZEB must be further diluted in an intravenous PVC infusion bag containing either 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer’s Injection, USP. For neonates, the INMAZEB solution should be diluted in 5% Dextrose Injection, USP (see Table 2). The total volume of the infusion solution to be administered is based on the patient’s body weight and is specified in Table 2.
- Select a diluent solution infusion bag of appropriate fill volume based on the patient’s body weight (see Table 2). Withdraw and discard from the bag a volume of diluent solution equal to the calculated dose in volume (mL) of INMAZEB. Then add the calculated volume of INMAZEB to the bag. For example:
- When using the 16.67 mg/16.67 mg/16.67 mg per mL solution for a 50 kg patient, withdraw and discard 150 mL of diluent from a 500 mL infusion bag. Then add 150 mL of INMAZEB to obtain a total infusion volume of 500 mL.
- When using the 33.33 mg/33.33 mg/33.33 mg per mL solution for a 50 kg patient, withdraw and discard 75 mL of diluent from a 500 mL infusion bag. Then add 75 mL of INMAZEB to obtain a total infusion volume of 500 mL.
|Body Weight (kg)||Total Infusion Volume After Dilution (mL)*||Infusion Time|
|0.5 to less than 1||7||4 hours|
|1 to 1.9||15|
|2 to 3.9||25||3 hours|
|4 to 7||50|
|8 to 15||100|
|16 to 38||250||2 hours|
|39 to 79||500|
|80 to 149||1,000|
|150 and above||2,000||4 hours|
- Mix the diluted solution by gentle inversion. Do not shake.
- INMAZEB does not contain preservatives. It is always recommended to administer intravenous medication immediately after preparation when possible. Store the diluted INMAZEB solution as specified in Table 3.
- Do not freeze the diluted solution.
- Discard any unused medicinal product or waste material.
|Diluent Used to Prepare Solution for Infusion||Diluted INMAZEB Solution Storage Conditions|
|0.9% Sodium Chloride Injection, USP||Store at room temperature up to 25°C (77°F) for no more than 8 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 24 hours.|
|5% Dextrose Injection, USP||Store at room temperature up to 25°C (77°F) for no more than 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 24 hours.|
|Lactated Ringer’s Injection, USP||Store at room temperature up to 25°C (77°F) for no more than 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 4 hours.|
- INMAZEB must be administered by a healthcare provider.
- Allow the diluted infusion solution to come to room temperature prior to administration.
- INMAZEB diluted with 5% Dextrose Injection, USP can be infused at temperatures up to 35°C (95°F). When the temperature is higher than 25°C (77°F), administer the diluted INMAZEB with 5% Dextrose Injection, USP immediately after completion of dose preparation.
- Administer the diluted infusion solution intravenously through an intravenous line containing a sterile, in-line or add-on 0.2-micron filter.
- The infusion rate is based on the patient’s body weight and prepared infusion volume. Select an appropriate infusion rate for the diluted infusion solution (see Table 2). It is important to follow the infusion time outlined in Table 2 based on the patient’s weight.
- The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events [see Warnings and Precautions (5.1)].
- Do not mix other medications with INMAZEB.
- Compatibility studies of INMAZEB have not been performed when co-administering other drugs simultaneously through the same infusion line.
INMAZEB is a clear to slightly opalescent and colorless to pale yellow solution available as:
- Injection: 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL) in a single-dose vial.
- Injection: 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL (33.33 mg/33.33 mg/33.33 mg per mL) in a single-dose vial.
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following INMAZEB infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care [see Adverse Reactions (6.1)].
Infusion could not be completed in 1% of subjects who received INMAZEB due to infusion-associated adverse events. The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events [see Adverse Reactions (6.1)].
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hypersensitivity Reactions Including Infusion-Associated Events [see Warnings and Precautions (5.1)]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates may not reflect the rates observed in practice.
Overall, 382 adult and pediatric subjects with Zaire ebolavirus infection received INMAZEB in one clinical trial (the PALM trial) and as part of an expanded access program conducted in the Democratic Republic of Congo during a Zaire ebolavirus outbreak in 2018-2019. In the PALM trial, the safety of INMAZEB was evaluated in a multi-center, open-label, randomized controlled trial, in which 154 subjects (115 adult subjects and 39 pediatric subjects) received INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] intravenously as a single infusion and 168 subjects received an investigational control [see Clinical Studies (14)]. All subjects received optimized standard of care treatment. During the same outbreak, INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] was given to 228 subjects (190 adult subjects and 38 pediatric subjects) in the expanded access program.
The safety data described below is derived from the PALM trial.
Table 4 summarizes adverse events that were reported during INMAZEB infusion. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Zaire ebolavirus infection. The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea, and vomiting. The adverse event profile in adult and pediatric subjects treated with INMAZEB was similar.
|Adverse Event *||INMAZEB(N=154)%||Control †(N=168)%|
|Pyrexia (Elevation in fever)||54||58|
The following pre-specified symptoms, which were assessed on a daily basis while admitted to the treatment unit, were reported in 40% or more of subjects who received INMAZEB: diarrhea, pyrexia, and vomiting. Evaluation of these symptoms may have been confounded by the underlying Zaire ebolavirus infection.
Discontinuation and Infusion Rate Adjustments in the PALM Trial
Approximately 99% of subjects who received INMAZEB in the PALM trial were able to complete their dose within three hours. Two subjects who received INMAZEB (1%) did not receive their complete infusion. One of the two subjects did not complete their INMAZEB infusion because of fever elevation [see Warnings and Precautions (5.1)].
Selected Laboratory Abnormalities in the PALM Trial
Table 5 presents selected laboratory abnormalities (worsening to Grade 3 or 4 compared to baseline) for adult and pediatric subjects in the PALM trial.
|Laboratory Test *||INMAZEBN=154%||ControlN=168%|
|ULN = upper limit of normal|
|Sodium, high ≥ 154 mmol/L||9||4|
|Sodium, low < 125 mmol/L||7||11|
|Potassium, high ≥ 6.5 mmol/L||13||12|
|Potassium, low < 2.5 mmol/L||9||8|
|Creatinine (mg/dL) ≥ 1.8 × ULN †||15||23|
|Alanine aminotransferase (U/L) ≥ 5 × ULN||10||14|
|Aspartate aminotransferase (U/L) ≥ 5 × ULN||21||18|
DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.